RMTI Rockwell Medical Inc.

1.04
+0.04  (+4%)
Previous Close 1
Open 1
52 Week Low 0.83
52 Week High 2.62
Market Cap $97,329,211
Shares 93,585,780
Float 81,032,739
Enterprise Value $58,843,780
Volume 1,200,889
Av. Daily Volume 2,251,274
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
IV Triferic
Anemia
Approved
Approved
FDA approval announced date March 27, 2020.
Soluble Ferric Pyrophosphate
Anemia
Approved
Approved
Approved January 26, 2015.

Latest News

  1. - 2020 revenue of $62.2 million -

    - Ended the year with $58.7 million in cash, cash equivalents and investments -

    - Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET -

    WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months and full year ended December 31, 2020.

    "2020 was an important year for us as we evolved our strategy to become a more medically-, scientifically- and data-driven company. There has been an evolution of both our management and Board…

    - 2020 revenue of $62.2 million -

    - Ended the year with $58.7 million in cash, cash equivalents and investments -

    - Conference call and webcast on Wednesday, March 31st at 4:30 p.m. ET -

    WIXOM, Mich., March 31, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today reported financial results and a business update for the three months and full year ended December 31, 2020.

    "2020 was an important year for us as we evolved our strategy to become a more medically-, scientifically- and data-driven company. There has been an evolution of both our management and Board of Directors, providing us with greater relevant experience," said Russell Ellison, M.D., M.Sc., President and Chief Executive Officer of Rockwell Medical. "We believe these changes support an improved execution of our strategy to accelerate Rockwell Medical's growth by creating and developing pharmaceutical products based on our Ferric Pyrophosphate Citrate ("FPC") technology for disease states where patients can benefit the most from an effective treatment for iron deficiency, while concurrently strengthening our dialysis business to drive incremental growth and efficiencies."

    Dr. Ellison added: "We've identified two areas beyond dialysis where we believe FPC will have the biggest impact: iron deficiency anemia in the home infusion setting and acute heart failure in hospitalized patients."

    Recent Operational Highlights

    Dialysis Business

    • Revenue from hemodialysis concentrates were $61.1 million in 2020.



    • Revenue from Triferic were approximately $1.1 million in 2020.



    • Results from a study, conducted by New York University and reported in Critical Care Medicine, showed $296,000 in cost savings from Triferic.



      The study, which was independent of Rockwell, reviewed the effects of long-term use of Triferic in a large outpatient dialysis clinic. The results showed substantial cost savings due to reductions in ESA and macromolecular IV iron use without impacting patient safety or hemoglobin targets.  In a retrospective data review of 100 patients that were followed before and after implementation of Triferic dialysate, there was a relative reduction in average weekly ESA dose of 26.4%, total use of IV iron replacement therapy decreased with a relative reduction in the use of all iron products (iron sucrose 65.7%, sodium ferric gluconate 98.2%) while anemia targets were met. This clinic determined that the reduction of these agents resulted in a net savings of more than $296,000 in one fiscal year.
    • Triferic AVNU (ferric pyrophosphate citrate injection), the IV formulation of Triferic, was made commercially available to patients in the United States.



    • Korea: In September 2020, Rockwell Medical partnered with Jeil Pharmaceutical Co., Ltd. for exclusive rights. In February 2021, Jeil filed a New Drug Application for Triferic (dialysate) and Triferic AVNU in Korea.



    • China: In January 2021, Wanbang Biopharmaceuticals enrolled the first patient in a pivotal Phase 3 trial.



    • India: In January 2020, Rockwell Medical and Sun Pharma entered into a licensing agreement, and Sun Pharma is in the regulatory process in India.



    • Canada: In May 2020, Rockwell Medical announced the filing of a New Drug Submission with Health Canada for Triferic AVNU.

    Home Infusion Program

    • The U.S. Food and Drug Administration (FDA) has accepted our proposed development strategy to pursue an approval via the 505(b)(1) pathway as a novel new drug application (NDA) for FPC for treatment of iron deficiency anemia (IDA) in adult patients in the home infusion setting. Pending a successful outcome of our pre-investigational new drug meeting with the FDA, the Company plans to initiate a clinical study during the second half of 2021.

    Pipeline Development

    • Rockwell Medical is exploring the use of its FPC platform for the treatment of hospitalized patients with acute heart failure. Management believes that FPC may deliver rapidly bioavailable iron to the heart and improve cardiac energetics. This effect could help patients recover faster, resulting in shorter hospital stays and fewer 30-day re-admissions. The Company plans to hold a Type C meeting with the FDA in the second half of 2021.

    2020 Corporate Updates

    • In December 2020, Rockwell Medical appointed industry leader and life science industry executive, Ms. Andrea Heslin Smiley, to its Board of Directors. Ms. Smiley brings commercial experience and a deep expertise in clinical nurse educators.



    • In September 2020, the Company appointed Russell L. Skibsted, M.B.A., as Executive Vice President, Chief Financial Officer and Chief Business Officer. Mr. Skibsted brings more than 25 years of experience in finance, global business development, capital raising, investor relations and operations.



    • In June 2020, Rockwell Medical appointed industry leader and renowned authority on kidney disease, Allen R. Nissenson, M.D., F.A.C.P., to its Board of Directors. Dr. Nissenson brings clinical, regulatory and public policy expertise, combined with his senior executive experience at a large dialysis organization.



    • In April 2020, the Company appointed Russell H. Ellison, M.D., M.Sc., as President and Chief Executive Officer. Dr. Ellison, who continues to serve as a member of the Board of Directors, brings broad medical, clinical development and corporate leadership experience to the role.



    • In March 2020, Rockwell Medical appointed Robert S. Radie to its Board of Directors. Mr. Radie brings more than three decades of industry experience, working in senior executive roles with both public and private pharmaceutical and biotech companies.

    Fourth Quarter and Full Year 2020 Selected Financial Highlights

    The following discussion and analysis should be read in conjunction with our audited condensed consolidated financial statements and related notes on Form 10-K for the year ended December 31, 2020.

    Revenues were $15.2 million and $62.2 million for the three months and year ended December 31, 2020, respectively, compared to $15.5 million and $61.3 million for the three months and year ended December 31, 2019, respectively. Triferic revenue was $0.5 million and $1.1 million for the three months and year ended December 31, 2020, respectively. Triferic was launched in Q2 2019 via the sample evaluation program.

    Cost of sales were $14.8 million and $59.5 million for the three months and year ended December 31, 2020, respectively, compared to $14.4 million and $58.5 million for the three months and year ended December 31, 2019, respectively. Cost of sales for the year ended December 31, 2020 resulted in gross profit of $2.7 million, compared to a gross profit of $2.8 million for the year ended December 31, 2019.

    Research and product development expenses were $1.9 million and $7.1 million for the three months and year ended December 31, 2020, respectively, compared to $2.0 million and $6.9 million for the three months and year ended December 31, 2019, respectively. The increase of $0.2 million year over year is related to clinical trials and other product development expenses for Triferic. The Company is continuing to invest in its medical and scientific programs to support the continued data and phase 4 clinical programs for Triferic in dialysis and the advancement of our FPC technology platform.

    Selling and marketing expenses were $2.1 million and $7.9 million for the three months and year ended December 31, 2020, respectively, compared to $1.9 million and $9.1 million for the three months and year ended December 31, 2019, respectively. The decrease of $1.2 million year over year is due primarily to the decrease in marketing costs of $2.3 million, partially offset by an increase in costs associated with hiring, training and educating new employees of $1.1 million. The fluctuation in these costs is mainly due to the timing of the Triferic (dialysate) launch in the third quarter of 2019. We expect lower quarter-to-quarter fluctuations in sales and marketing costs going forward.

    General and administrative expenses were $4.4 million and $16.2 million for the three months and year ended December 31, 2020, respectively, compared to $4.7 million and $21.0 for the three months and year ended December 31, 2019, respectively. The $4.8 million decrease year over year was driven primarily by decreases to stock compensation, legal, recruiting and consulting fees, partially offset by an increase in labor costs. The decrease in stock compensation primarily relate to the resignation of our former President and Chief Executive Officer, Stuart Paul, in April 2020 and former Chief Financial Officer effective July 2020.

    Net loss was $8.7 million, or $(0.09) basic and diluted net loss per share, and $30.9 million, or $(0.41) basic and diluted net loss per share, for the three months and year ended December 31, 2020, respectively, compared to net loss of $7.3 million, or $(0.11) basic and diluted net loss per share, and $34.1 million, or $(0.56) basic and diluted net loss per share, for the three months and year ended December 31, 2019, respectively.

    Cash, cash equivalents, and investments available-for-sale totaled $58.7 million as of December 31, 2020, compared to $67.3 million on September 30, 2020. Working capital was $56.7 million as of December 31, 2020, compared to $65.2 million as of September 30, 2020.

    The Company has a debt facility of $35.0 million of which the first tranche of $22.5 million was funded in March 2020 and is classified as long-term debt on the balance sheet. The Company may be eligible to draw on a third tranche of $7.5 million upon the achievement of certain additional milestones, including the achievement of certain Triferic sales thresholds.

    As of December 31, 2020, there were 93,573,165 shares of common stock outstanding.

    Fourth Quarter and Full Year 2020 and Business Update Conference Call and Webcast

    Rockwell Medical's management team will host a conference call and audio webcast today, March 31, 2021, at 4:30 p.m. ET to discuss Q4 and Full Year 2020 financial results and provide a business update.

    To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 6154055. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

    About Triferic Dialysate and Triferic AVNU

    Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

    Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to replace the ongoing losses to maintain hemoglobin without increasing iron stores. Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body), which is then transported to the bone marrow to be incorporated into hemoglobin. Because of this unique mechanism of action, there is no increase in ferritin (a measure of stored iron). Triferic and Triferic AVNU address a significant medical need in treating functional iron deficiency in end-stage kidney disease patients.

    The safety profile of Triferic is similar to placebo in controlled clinical trials in patients with end-stage kidney disease. Since approval, there have been no safety related changes to the product labeling.

    IMPORTANT SAFETY INFORMATION FOR TRIFERIC AND TRIFERIC AVNU

    INDICATION

    TRIFERIC and TRIFERIC AVNU are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    Limitations of Use

    TRIFERIC and TRIFERIC AVNU are not intended for use in patients receiving peritoneal dialysis. TRIFERIC and TRIFERIC AVNU have not been studied in patients receiving home hemodialysis.

    Warnings and Precautions

    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials.

    Iron status should be determined on pre-dialysis blood samples. Post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

    Adverse Reactions

    Most common adverse reactions (incidence ≥3% and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

    To report an Adverse Events (AE) or Product Quality Control (PQC) please call the Medical Information Department at (855) 333-4315 or e-mail at .

    For full Safety and Prescribing Information please visit www.Triferic.com and www.Trifericavnu.com.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease. Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the effectiveness of FPC in other indications, Triferic's ability to generate cost savings, our ability to grow our dialysis business, the development plans and timing for Rockwell Medical's FPC pipeline candidates, the timing and outcome of meetings with the FDA, the timing and outcome of foreign clinical trials and regulatory approval, the timing for the commencement of our clinical trial of FPC for treatment of IDA in adult patients in the home infusion setting and future trends related to our sales and marketing costs. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend" and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: the continuance of the COVID-19 pandemic (including, applicable federal state or local orders) on business and operating results, including our supply chain, dialysis concentrates business and the Company's commercialization of both pharmaceutical and medical device products; the challenges inherent in new product development, other new indications and therapeutics areas for our products; the success of our commercialization of Triferic (dialysate) and Triferic AVNU; the success and timing of international clinical trials for Triferic Dialysate; the success and timing of international regulatory and reimbursement approval for Triferic (dialysate) and Triferic AVNU; the success of our commercial launch of Triferic AVNU in the United States; the success and timing of the development of our FPC pipeline candidates, the risk that topline clinical data and real world data results may not demonstrate efficacy or may not be predictive of future results; expected financial performance, including cash flows, revenues, growth, margins, funding, liquidity and capital resources; and those risks more fully discussed in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2020, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

    Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.



    Financial Tables Follow

    ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

    Condensed Consolidated Balance Sheets

    (Dollars in Thousands)

    (Unaudited)

            
     December 31,     December 31,   
     2020

     2019

      
            
    ASSETS       
    Cash and Cash Equivalents$48,682  $11,795   
    Investments Available-for-Sale 9,997   14,250   
    Accounts Receivable, net of a reserve of $9 for both 2020 and 2019 4,171   4,203   
    Inventory 3,913   3,647   
    Prepaid and Other Current Assets 2,706   2,979   
    Total Current Assets 69,469   36,874   
    Property and Equipment, net 2,642   2,433   
    Inventory, Non-Current 1,176   441   
    Right of Use Assets, net 2,911   3,213   
    Goodwill 921   921   
    Other Non-current Assets 629   435   
    Total Assets$77,748  $44,317   
    LIABILITIES AND STOCKHOLDERS' EQUITY       
    Accounts Payable$4,155  $3,018   
    Accrued Liabilities 5,013   4,518   
    Settlement Payable    104   
    Lease Liability - Current 1,167   1,493   
    Deferred License Revenue 2,175   2,234   
    Insurance Financing Note Payable    763   
    Customer Deposits 152   55   
    Other Current Liability - Related Party 131   189   
    Total Current Liabilities 12,793   12,374   
            
    Lease Liability - Long Term 1,821   1,781   
    Term Loan, Net of Issuance Costs 20,949      
    Deferred License Revenue 8,015   9,842   
    Total Liabilities 43,578   23,997   
            
    Stockholders' Equity:       
    Preferred Shares, $0.0001 par value, 2,000,000 shares authorized, no shares issued and outstanding at December 31, 2020 and 2019       
    Common Stock, $0.0001 par value,170,000,000 shares authorized, 93,573,165 and 65,378,890 shares issued and outstanding at December 31, 2020 and 2019, respectively 9   7   
    Additional Paid-in Capital 371,510   326,777   
    Accumulated Deficit (337,406)  (306,516)  
    Accumulated Other Comprehensive Income 57   52   
    Total Stockholders' Equity  34,170   20,320   
    Total Liabilities And Stockholders' Equity$77,748  $44,317   
            
            

    ROCKWELL MEDICAL, INC. AND SUBSIDIARIES

    Condensed Consolidated Statements of Operations

    (Dollars in Thousands, except per share amounts)

    (Unaudited)

         
         Three Months Ended December 31, 2020    Three Months Ended December 31, 2019    Year Ended December 31, 2020    Year Ended December 31, 2019  
                   
    Net Sales $15,164  $15,490  $62,197  $61,303   
    Cost of Sales  14,780   14,379   59,472   58,464   
    Gross Profit (Loss)  384   1,111   2,725   2,839   
    Research and Product Development  1,909   1,956   7,092   6,886   
    Selling and Marketing  2,133   1,901   7,871   9,050   
    General and Administrative  4,416   4,657   16,182   20,998   
    Settlement Expense, net of Reimbursement           430   
    Operating Loss  (8,074)  (7,403)  (28,420)  (34,525)  
                   
    Other Income (Expense)              
    Realized Gain (Loss) on Investments     6   8   30   
    Warrant Modification Expense        (837)     
    Interest Expense  (588)  (8)  (1,879)  (25)  
    Interest Income  (2)  103   238   392   
    Total Other Income  (590)  101   (2,470)  397   
                   
    Net Loss $(8,664) $(7,302) $(30,890) $(34,128)  
                   
                   
    Basic and Diluted Net Loss per Share $(0.09) $(0.11) $(0.41) $(0.56)  
                   
    Basic and Diluted Weighted Average Shares Outstanding  93,573,165   64,450,030   75,621,674   60,918,544   
                   



    CONTACTS

    Investors:

    Argot Partners

    212.600.1902

    Media:

    David Rosen

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
  2. WIXOM, Mich., March 18, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Wednesday, March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the three months and full year ended December 31, 2020, and recent operational highlights.

    To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 6154055. A live webcast of the call will be available under "Events & Presentations" in the Investor…

    WIXOM, Mich., March 18, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Wednesday, March 31, 2021, at 4:30 p.m. ET to discuss its financial results for the three months and full year ended December 31, 2020, and recent operational highlights.

    To access the conference call, please dial (877) 383-7438 (local) or (678) 894-3975 (international) at least 10 minutes prior to the start time and refer to conference ID 6154055. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

    To submit questions in advance, please email your questions to .

    About Triferic Dialysate and Triferic AVNU

    Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

    Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to replace the ongoing losses to maintain hemoglobin without increasing iron stores. Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body), which is then transported to the bone marrow to be incorporated into hemoglobin. Because of this unique mechanism of action, there is no increase in ferritin (a measure of stored iron). Triferic and Triferic AVNU address a significant medical need in treating functional iron deficiency in end-stage kidney disease patients.

    The safety profile of Triferic is similar to placebo in controlled clinical trials in patients with end-stage kidney disease. Since approval, there have been no safety related changes to the product labeling.

    IMPORTANT SAFETY INFORMATION FOR TRIFERIC AND TRIFERIC AVNU

    INDICATION

    TRIFERIC and TRIFERIC AVNU are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    Limitations of Use

    TRIFERIC and TRIFERIC AVNU are not intended for use in patients receiving peritoneal dialysis. TRIFERIC and TRIFERIC AVNU have not been studied in patients receiving home hemodialysis.

    Warnings and Precaution

    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials.

    Iron status should be determined on pre-dialysis blood samples. Post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

    Adverse Reactions

    Most common adverse reactions (incidence ≥3% and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

    To report an Adverse Events (AE) or Product Quality Control (PQC) please call the Medical Information Department at (855) 333-4315 or e-mail at .

    For full Safety and Prescribing Information please visit www.Triferic.com and www.Trifericavnu.com.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease. Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

    Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All Company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

    CONTACTS

    Investors:

    Argot Partners

    212.600.1902

    Media:

    David Rosen

    Argot Partners

    212.600.1902

     



    Primary Logo

    View Full Article Hide Full Article
  3. WIXOM, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright Global Life Sciences Conference.

    The pre-recorded presentation will be available on March 9, 2021, at 1:30 p.m. Eastern Time in the "Investors" section of the Company's website at www.rockwellmed.com. A replay of the webcast will be archived on the Company's website for 30 days.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency…

    WIXOM, Mich., March 04, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that members of its executive management team are scheduled to present at the H.C. Wainwright Global Life Sciences Conference.

    The pre-recorded presentation will be available on March 9, 2021, at 1:30 p.m. Eastern Time in the "Investors" section of the Company's website at www.rockwellmed.com. A replay of the webcast will be archived on the Company's website for 30 days.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease. Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

    About Triferic Dialysate and Triferic AVNU

    Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

    Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to replace the ongoing losses to maintain hemoglobin without increasing iron stores. Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body), which is then transported to the bone marrow to be incorporated into hemoglobin. Because of this unique mechanism of action, there is no increase in ferritin (a measure of stored iron). Triferic and Triferic AVNU address a significant medical need in treating functional iron deficiency in end-stage kidney disease patients.

    The safety profile of Triferic is similar to placebo in controlled clinical trials in patients with end-stage kidney disease. Since approval, there have been no safety related changes to the product labeling.

    IMPORTANT SAFETY INFORMATION FOR TRIFERIC AND TRIFERIC AVNU

    INDICATION

    TRIFERIC and TRIFERIC AVNU are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    Limitations of Use

    TRIFERIC and TRIFERIC AVNU are not intended for use in patients receiving peritoneal dialysis. TRIFERIC and TRIFERIC AVNU have not been studied in patients receiving home hemodialysis.

    Warnings and Precaution

    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials.

    Iron status should be determined on pre-dialysis blood samples. Post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

    Adverse Reactions

    Most common adverse reactions (incidence ≥3% and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

    To report an Adverse Events (AE) or Product Quality Control (PQC) please call the Medical Information Department at (855) 333-4315 or e-mail at .

    For full Safety and Prescribing Information please visit www.Triferic.com and www.Trifericavnu.com.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the impact of COVID-19 on Rockwell Medical's business and operations, the commercialization of Triferic Dialysate, the launch and commercialization of Triferic AVNU, the commercialization and applicability of Triferic AVNU in international markets, and the development plans and timing for Rockwell Medical's FPC pipeline candidates. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic (including, applicable federal state or local orders) on business and operating results, including our supply chain, dialysis concentrates business, the commercial launch of Triferic AVNU, and the ability to secure international partners; the challenges inherent in new product development and other indications and therapeutics areas for our products; the success of our commercialization strategy; the success and timing of our commercialization of Triferic Dialysate; the success and timing of international clinical trials for Triferic Dialysate and Triferic AVNU; the success and timing of our commercial launch of Triferic AVNU in the United States; the ability to manufacture Triferic Dialysate and Triferic AVNU in a cost effective manner; the reimbursement of Triferic Dialysate and Triferic AVNU in international markets; the success and timing of the development of our FPC pipeline candidates, the risk that topline clinical data and real world results may not be predictive of future results; expected financial performance, including cash flows, revenues, growth, margins, funding, liquidity and capital resources; and those risks more fully discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended September 30, 2020 and of our Annual Report on Form 10-K for the year ended December 31, 2019, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

    Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

    CONTACTS

    Investors:

    Argot Partners

    212.600.1902

    Media:

    David Rosen

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
  4. WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU (ferric pyrophosphate citrate injection), the intravenous (IV) formulation of Triferic, is now available to patients in the United States. Triferic AVNU was approved by the U.S. Food and Drug Administration (FDA) in March 2020 and is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    "The commercial availability of Triferic AVNU is good news for patients with chronic kidney…

    WIXOM, Mich., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that Triferic AVNU (ferric pyrophosphate citrate injection), the intravenous (IV) formulation of Triferic, is now available to patients in the United States. Triferic AVNU was approved by the U.S. Food and Drug Administration (FDA) in March 2020 and is indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    "The commercial availability of Triferic AVNU is good news for patients with chronic kidney disease on hemodialysis and their healthcare providers. This IV formulation is an important line extension of Triferic Dialysate," said Russell Ellison, M.D., M.Sc., President and Chief Executive Officer of Rockwell Medical. "With Triferic AVNU, more patients will have access to the benefits of Triferic as providers will have added flexibility to administer the IV formulation to their patients who may benefit from physiologic iron maintenance therapy to manage their anemia."

    Triferic is a novel, physiologic iron maintenance therapy that provides bioavailable iron to replace iron lost during every dialysis treatment and maintain hemoglobin. While Triferic Dialysate is designed to be administered via liquid bicarbonate, Triferic AVNU is designed for direct IV infusion, which provides hemodialysis patients with greater access to the Triferic platform and expands administration options for clinicians. Triferic AVNU can be administered regardless of a dialysis center's mode of bicarbonate delivery. Many dialysis centers in international markets and an increasing number of dialysis centers in the U.S. have converted to the use of dry bicarbonate cartridges or bags and online dialysate generation, which is not compatible with Triferic Dialysate.

    Triferic AVNU is available for commercial purchase directly through Rockwell Medical and our exclusive distributor, Metro Medical™, a Cardinal Health company, to expand market availability and ease of ordering. Metro Medical has a long history as a leading distributor of pharmaceuticals and medical supplies to nephrology practices and clinic-based dialysis centers in the U.S., the focus market for Triferic ANVU.

    About Triferic Dialysate and Triferic AVNU

    Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

    Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to replace the ongoing losses to maintain hemoglobin without increasing iron stores. Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body), which is then transported to the bone marrow to be incorporated into hemoglobin. Because of this unique mechanism of action, there is no increase in ferritin (a measure of stored iron). Triferic and Triferic AVNU address a significant medical need in treating functional iron deficiency in end-stage kidney disease patients.

    The safety profile of Triferic is similar to placebo in controlled clinical trials in patients with end-stage kidney disease. Since approval, there have been no safety related changes to the product labeling.

    IMPORTANT SAFETY INFORMATION FOR TRIFERIC AND TRIFERIC AVNU

    INDICATION

    TRIFERIC and TRIFERIC AVNU are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    Limitations of Use

    TRIFERIC and TRIFERIC AVNU are not intended for use in patients receiving peritoneal dialysis. TRIFERIC and TRIFERIC AVNU have not been studied in patients receiving home hemodialysis.

    Warnings and Precautions

    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials.

    Iron status should be determined on pre-dialysis blood samples. Post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

    Adverse Reactions

    Most common adverse reactions (incidence ≥3% and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

    To report an Adverse Events (AE) or Product Quality Control (PQC) please call the Medical Information Department at (855) 333-4315 or e-mail at .

    For full Safety and Prescribing Information please visit www.Triferic.com and www.Trifericavnu.com.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease. Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the impact of COVID-19 on Rockwell Medical's business and operations, the commercialization of Triferic Dialysate, the launch and commercialization of Triferic AVNU, the commercialization and applicability of Triferic AVNU in international markets, and the development plans and timing for Rockwell Medical's FPC pipeline candidates. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic (including, applicable federal state or local orders) on business and operating results, including our supply chain, dialysis concentrates business, the commercial launch of Triferic AVNU, and the ability to secure international partners; the challenges inherent in new product development and other indications and therapeutics areas for our products; the success of our commercialization strategy; the success and timing of our commercialization of Triferic Dialysate; the success and timing of international clinical trials for Triferic Dialysate and Triferic AVNU; the success and timing of our commercial launch of Triferic AVNU in the United States; the ability to manufacture Triferic Dialysate and Triferic AVNU in a cost effective manner; the reimbursement of Triferic Dialysate and Triferic AVNU in international markets; the success and timing of the development of our FPC pipeline candidates, the risk that topline clinical data and real world results may not be predictive of future results; expected financial performance, including cash flows, revenues, growth, margins, funding, liquidity and capital resources; and those risks more fully discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended September 30, 2020 and of our Annual Report on Form 10-K for the year ended December 31, 2019, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

    Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

    CONTACTS

    Investors:

    Argot Partners

    212.600.1902

    Media:

    David Rosen

    Argot Partners

    212.600.1902

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0f76fe57-5fe6-4f9e-b2ad-b78737f253a9

     



    Primary Logo

    View Full Article Hide Full Article
  5. WIXOM, Mich., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd., filed New Drug Applications (NDA) with the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic AVNU and Triferic Dialysate for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.

    "The NDA submissions by our partner, Jeil Pharmaceutical, is an important milestone for Rockwell Medical as well as for the more than 82,000 patients in South Korea undergoing hemodialysis…

    WIXOM, Mich., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (NASDAQ:RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and iron deficiency anemia management, today announced that its partner in South Korea, Jeil Pharmaceutical Co., Ltd., filed New Drug Applications (NDA) with the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea for Triferic AVNU and Triferic Dialysate for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease.

    "The NDA submissions by our partner, Jeil Pharmaceutical, is an important milestone for Rockwell Medical as well as for the more than 82,000 patients in South Korea undergoing hemodialysis," said Russell Ellison, M.D., M.Sc., President and Chief Executive Officer of Rockwell Medical. "We expect Triferic to become an important new treatment option for dialysis clinics and the patients they serve, if approved by the MFDS. We look forward to continuing our productive relationship with Jeil as they advance both Triferic presentations through the regulatory process."

    In September 2020, Rockwell Medical entered into an exclusive license agreement with Jeil for the rights to commercialize Triferic in South Korea. Under the terms of the license agreement, Jeil will be the exclusive development and commercialization partner for Triferic in South Korea. In consideration for the license, Rockwell Medical received an upfront fee and will be eligible for milestone payments and royalties on net sales.

    About Rockwell Medical

    Rockwell Medical is a biopharmaceutical company dedicated to transforming iron deficiency and anemia management in a wide variety of therapeutic areas and across the globe, improving the lives of very sick patients. The Company's initial focus is the treatment of anemia in end-stage kidney disease. Rockwell Medical's exclusive renal drug therapies, Triferic (ferric pyrophosphate citrate) Dialysate and Triferic AVNU, are the only FDA-approved therapeutics indicated for maintenance of hemoglobin in hemodialysis patients. Rockwell Medical is also an established manufacturer, supplier and leader in delivering high-quality hemodialysis concentrates/dialysates to dialysis providers and distributors in the U.S. and abroad.

    About Triferic Dialysate and Triferic AVNU

    Triferic Dialysate and Triferic AVNU are the only FDA-approved therapies in the U.S. indicated to replace iron and maintain hemoglobin in hemodialysis patients during each dialysis treatment. Triferic Dialysate and Triferic AVNU have a unique and differentiated mechanism of action, which has the potential to benefit patients and health care economics. Triferic Dialysate and Triferic AVNU represent a potential innovative medical advancement in hemodialysis patient iron management – with the potential to become the future standard of care.

    Triferic Dialysate and Triferic AVNU both deliver approximately 5-7 mg iron with every hemodialysis treatment to replace the ongoing losses to maintain hemoglobin without increasing iron stores. Both formulations donate iron immediately and completely to transferrin (carrier of iron in the body), which is then transported to the bone marrow to be incorporated into hemoglobin. Because of this unique mechanism of action, there is no increase in ferritin (a measure of stored iron). Triferic and Triferic AVNU address a significant medical need in treating Functional Iron Deficiency in end-stage kidney disease patients.

    The safety profile of Triferic is similar to placebo in controlled clinical trials in patients with end-stage kidney disease. Since approval, there have been no safety related changes to the product labeling.

    Important Safety Information

    TRIFERIC and TRIFERIC AVNU are indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD).

    TRIFERIC is not intended for use in patients receiving peritoneal dialysis. TRIFERIC has not been studied in patients receiving home hemodialysis.

    Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving parenteral iron products. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after hemodialysis until clinically stable. Personnel and therapies should be immediately available for the treatment of serious hypersensitivity reactions. Hypersensitivity reactions have been reported in 1 (0.3%) of 292 patients receiving TRIFERIC in two randomized clinical trials. Iron status should be determined on pre-dialysis blood samples. Post-dialysis serum iron parameters may overestimate serum iron and transferrin saturation.

    Most common adverse reactions (incidence ≥3% and at least 1% greater than placebo) in controlled clinical studies include: headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.

    Forward-Looking Statements

    Certain statements in this press release may constitute "forward-looking statements" within the meaning of the federal securities laws, including, but not limited to, the receipt milestone payments and royalties by Rockwell Medical, the timing of product sales in South Korea, the receipt of regulatory approvals in South Korea and the potential market opportunity for Triferic in South Korea. Words such as, "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "could," "can," "would," "develop," "plan," "potential," "predict," "forecast," "project," "intend" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward looking statements. While Rockwell Medical believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Rockwell Medical's SEC filings), many of which are beyond our control and subject to change. Actual results could be materially different. Risks and uncertainties include, but are not limited to: the impact of the COVID-19 pandemic (including, applicable federal, state or local orders) on business and operating results; receipt of regulatory approval for Triferic in South Korea; our ability to successfully launch both formulations of Triferic which will impact Rockwell's ability to achieve milestones and receive royalty payments; the ability to manufacturer the product in accordance with South Korean regulations, anticipated market opportunity in South Korea; and those risks more fully discussed in the "Risk Factors" section of our Quarterly Report on Form 10-Q for the period ended June 30, 2020 and of our Annual Report on Form 10-K for the year ended December 31, 2019, as such description may be amended or updated in any future reports we file with the SEC. Rockwell Medical expressly disclaims any obligation to update our forward-looking statements, except as may be required by law.

    Triferic® is a registered trademark of Rockwell Medical, Inc. Triferic AVNU is pending with the U.S. Patent and Trademark Office. All other product names, logos, and brands are property of their respective owners in the United States and/or other countries. All company, product and service names used on this website are for identification purposes only. Use of these names, logos, and brands does not imply endorsement.

    CONTACTS

    Investors:

    Argot Partners

    212.600.1902

    Media:

    David Rosen

    Argot Partners

    212.600.1902



    Primary Logo

    View Full Article Hide Full Article
View All Rockwell Medical Inc. News